Journal of Oncology Pharmacy Practice最新文献

Characteristics and outcomes of low-grade and high-grade pancreatic immune-related adverse events at a single center. 单一中心低级别和高级别胰腺免疫相关不良事件的特征和结局

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-11 DOI: 10.1177/10781552251348662

Reema Patel, Zakary Kolkey, Joslyn Jung, Omar Elghawy, Abhishek Mullapudi, Jessica Xu, Varinder Kaur

{"title":"Characteristics and outcomes of low-grade and high-grade pancreatic immune-related adverse events at a single center.","authors":"Reema Patel, Zakary Kolkey, Joslyn Jung, Omar Elghawy, Abhishek Mullapudi, Jessica Xu, Varinder Kaur","doi":"10.1177/10781552251348662","DOIUrl":"https://doi.org/10.1177/10781552251348662","url":null,"abstract":"ObjectiveImmune checkpoint inhibitors (ICIs) are widely utilized in treating various malignancies but are associated with immune-related adverse events (irAEs), which often poses challenges to their use. Pancreatic irAEs, though rare, can present as new-onset diabetes, pancreatitis, or asymptomatic lipase elevation, often altering the clinical trajectory and quality of life of patients. This study sought to expand the understanding of this rare toxicity by summarizing the characteristics and outcomes of low-grade and high-grade pancreatic irAEs.MethodsWe conducted a single-center, retrospective study of adult patients treated with checkpoint inhibitors between 2010 and 2022. Patients with clinical or radiographic evidence of pancreatic injury associated with ICI therapy were included. Pancreatic irAEs were defined as low-grade (< grade 3) or high-grade (≥ grade 3) using the Common Terminology Criteria for Adverse Events.ResultsOf 21 patients identified with pancreatic irAEs, 76% (n = 16) experienced high-grade severity, often requiring hospitalization. The majority of patients presented with either new-onset diabetes (n = 11) or pancreatitis (n = 11). Most low-grade irAEs resolved, while the majority of high-grade events did not, particularly due to the lasting nature of insulin-dependent diabetes. ICI rechallenge was attempted in most cases, although conclusions regarding subsequent disease and survival outcomes are limited.ConclusionsPancreatic irAEs, though uncommon, often present at higher toxicity grades at onset and require substantial medical intervention, whether acutely in the hospital or longitudinally in the outpatient setting. Early identification and management remain critical, and ICI rechallenge appears to be feasible in select patients. Further research is required to better predict and manage severe pancreatic irAEs.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251348662"},"PeriodicalIF":1.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Development and validation of a web-based platform for streamlining chemotherapy management in oncology". “简化肿瘤学化疗管理的网络平台的开发和验证”。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-11 DOI: 10.1177/10781552251345433

G Hari Prakash, Sunil Kumar D, Kiran Pk, Vanishri Arun, Deepika Yadav, Arun Gopi

{"title":"\"Development and validation of a web-based platform for streamlining chemotherapy management in oncology\".","authors":"G Hari Prakash, Sunil Kumar D, Kiran Pk, Vanishri Arun, Deepika Yadav, Arun Gopi","doi":"10.1177/10781552251345433","DOIUrl":"https://doi.org/10.1177/10781552251345433","url":null,"abstract":"BackgroundEffective chemotherapy management is crucial for optimal patient outcomes, yet it remains complex and multifaceted. This study aimed to develop and validate a comprehensive web-based platform, OncoCare, designed to streamline chemotherapy management for healthcare providers and improve medication adherence among patients undergoing chemotherapy treatment.MethodologyThe OncoCare platform was developed through a user-centric approach, and the platform's efficacy was evaluated in a two-part study: Part 1 assessed healthcare provider satisfaction using a pre-post design, and Part 2 employed a quasi-experimental trial to compare medication adherence levels between an experimental group using the platform and a control group receiving standard care.ResultsHealthcare provider satisfaction significantly improved after one month of using the OncoCare platform, with mean scores increasing from 14.8 (moderate satisfaction) at baseline to 25.6 (high satisfaction) at follow-up (p = 0.001). In the patient evaluation, the experimental group exhibited a substantial decrease in low adherence (from 80.0% to 16.7%) and a significant increase in moderate adherence (66.6%) compared to the control group (p = 0.002).ConclusionThe OncoCare web-based platform demonstrated potential in enhancing chemotherapy management for healthcare providers and improving medication adherence among patients undergoing chemotherapy treatment.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251345433"},"PeriodicalIF":1.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Questionnaire survey on efforts and challenges in cardio-oncology among pharmacists: A cross-sectional survey of the pharmacists of the Japanese Onco-Cardiology Society. 药师在心脏肿瘤学方面的努力与挑战的问卷调查：日本肿瘤-心脏病学会药师横断面调查。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-11 DOI: 10.1177/10781552251349135

Yuma Shibutani, Makoto Hiraide

{"title":"Questionnaire survey on efforts and challenges in cardio-oncology among pharmacists: A cross-sectional survey of the pharmacists of the Japanese Onco-Cardiology Society.","authors":"Yuma Shibutani, Makoto Hiraide","doi":"10.1177/10781552251349135","DOIUrl":"https://doi.org/10.1177/10781552251349135","url":null,"abstract":"IntroductionCardiovascular disease may develop in association with cancer treatment. Pharmacists are involved in the care of patients requiring cardio-oncology services, but the efforts made and the challenges experienced by pharmacists are unclear.MethodsThe 61 pharmacists affiliated with the Japanese Onco-Cardiology Society (JOCS) were surveyed through a Google Forms questionnaire about their efforts and challenges in cardio-oncology, as well as their education and research motivation.ResultsTwenty of the 61 pharmacists responded to the survey. The cardiovascular adverse events that required the most caution for 85% of respondents were cancer treatment-related cardiac dysfunction and heart failure. A particularly common specific approach of pharmacists was to suggest echocardiography and electrocardiography before and during treatment. Of the identified challenges in cardio-oncology, the lack of a follow-up system for late toxicity, and lack of pharmacists' knowledge of cardio-oncology, were reported. Scientific conferences were the most used to learn about cardio-oncology. As requests for learning content, the respondents indicated that seminars for pharmacists in the fields of oncology and cardiovascular disease should be held and books should be produced, a study group of pharmacists established, and a platform for sharing information created. Ninety percent of respondents institutions were conducting cardio-oncology research. Additionally, all respondents were interested in pharmacist-initiated multicenter trials.ConclusionsJOCS member pharmacists were found to be actively involved in the management of cardiotoxicity associated with cancer treatment. This study suggests that pharmacists' activities contribute to the improvement of cardio-oncology.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251349135"},"PeriodicalIF":1.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in preventative bone health measures in prostate cancer: A cross-sectional study of patients at Calderdale and Huddersfield NHS foundation trust. 前列腺癌预防骨健康措施的趋势：卡尔德代尔和哈德斯菲尔德NHS基金会信托患者的横断面研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-11 DOI: 10.1177/10781552251349490

Milly Finch, Richard Jacques

{"title":"Trends in preventative bone health measures in prostate cancer: A cross-sectional study of patients at Calderdale and Huddersfield NHS foundation trust.","authors":"Milly Finch, Richard Jacques","doi":"10.1177/10781552251349490","DOIUrl":"https://doi.org/10.1177/10781552251349490","url":null,"abstract":"BackgroundThere have been significant advances within the treatment of prostate cancer in recent years, which have had a positive impact on what has been historically a poor prognosis disease with limited treatment options. However, no treatment is without risk and adverse effects many of the treatment options are known to cause osteoporosis, fractures, and a reduction in bone mineral density.MethodsA retrospective cross-sectional observational study involving secondary data analysis of 414 patients was used. Patients were split into three cohorts, cohort one- locally advanced prostate cancer treated with radiotherapy and 3 years of androgen deprivation therapy, cohort two- oligometastatic disease who receive first line radiotherapy and cohort three- metastatic prostate cancer encompassing hormone sensitive and castrate resistant disease.ResultsAnalysis demonstrated the differing bone health interventions given or prescribed to prostate cancer: lifestyle advice, calcium and vitamin D supplements and bisphosphonates. Patients in cohort one had an overall prevalence of 21.8% given lifestyle advice, 15.2% prescribed calcium and vitamin D supplements and 7.3% prescribed bisphosphonates. Patients in cohort two had an overall prevalence of 2.4% given lifestyle advice, 22% prescribed calcium and vitamin D supplements and 7.3% prescribed bisphosphonates. Patients in cohort three had an overall prevalence of 9.6% given lifestyle advice, 67.3% prescribed calcium and vitamin D supplements and 43.8% prescribed bisphosphonates.ConclusionThe study showed gaps in current cancer management when compared to the clinical recommendations. Having professional bodies clinical consensus on the topic would create clear guidance for clinicians to provide a more holistic overview.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251349490"},"PeriodicalIF":1.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cyclophosphamide and Etoposide: A mathematical evaluation of the decay of two highly reactive molecules. 环磷酰胺和依托泊苷：两个高活性分子衰变的数学评价。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-11 DOI: 10.1177/10781552251342214

Cristina Filosa, Nicola Antonio Colabufo, Marcello Leopoldo, Donatella Telesca, Maria Rita Milella, Carmela Mazzoccoli, Alfredo Tartarone, Antonio Prospero Colasurdo, Rosa Lerose

{"title":"Cyclophosphamide and Etoposide: A mathematical evaluation of the decay of two highly reactive molecules.","authors":"Cristina Filosa, Nicola Antonio Colabufo, Marcello Leopoldo, Donatella Telesca, Maria Rita Milella, Carmela Mazzoccoli, Alfredo Tartarone, Antonio Prospero Colasurdo, Rosa Lerose","doi":"10.1177/10781552251342214","DOIUrl":"https://doi.org/10.1177/10781552251342214","url":null,"abstract":"Cyclophosphamide and Etoposide are two antineoplastic drugs that are commonly employed in the treatment of several types of cancer, including prostate, stomach, and lung cancer, as well as multiple myeloma and sarcoma. The course of treatment often involves a mixture of etoposide and cyclophosphamide with other molecules, such as cisplatin for the former, or dactinomycin and vincristine for the latter. In this study, two separate analytical methods are proposed to evaluate the stability and the decay of Cyclophosphamide and Etoposide solutions prepared in normal saline and glucose (5%). The solutions of each antineoplastic drug were prepared by the IRCCS CROB RIONERO at three separate dosages and were submitted to HPLC-UV apparatus for the analysis. Firstly, two calibration curves were carried out to validate the method; secondly, samples of each solution were taken at specific time points to evaluate the decay in concentration of the molecules. The results show a stark decrease in stability of etoposide at increasing drug concentrations. On the other hand, cyclophosphamide is known for being highly unstable after reconstitution, therefore its decay was expected at each dosage. The data obtained by the triplicate analysis of both drugs at each time point was then used to mathematically evaluate the decay pattern of each molecule.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251342214"},"PeriodicalIF":1.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying health disparities in lenalidomide access. 确定来那度胺获取方面的健康差异。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-11 DOI: 10.1177/10781552251348222

Ngan N Nguyen, Justin P Huynh, Jenna J Wu, Hannah M Kisla, Jamie N Read, Annabel G La, Darlene Tat, Britny R Brown

{"title":"Identifying health disparities in lenalidomide access.","authors":"Ngan N Nguyen, Justin P Huynh, Jenna J Wu, Hannah M Kisla, Jamie N Read, Annabel G La, Darlene Tat, Britny R Brown","doi":"10.1177/10781552251348222","DOIUrl":"https://doi.org/10.1177/10781552251348222","url":null,"abstract":"IntroductionLenalidomide is dispensed through a limited distribution network, leading to longer prescription fill times. Acquiring lenalidomide involves navigating the risk evaluation and mitigation strategies (REMS) program, insurance prior authorization, and financial assistance for out-of-pocket costs. Health disparities, including socioeconomic status, health literacy, language barriers, and geography, can further delay access. This study aimed to identify and analyze factors contributing to delays in access to lenalidomide.MethodsThis retrospective study used electronic health records within the Brown University Health system to identify adults newly diagnosed with hematologic malignancies between June 1, 2019 and June 1, 2024, with a lenalidomide prescription. A stepwise multiple linear regression evaluated factors affecting dispensation time. The primary endpoint was to identify factors contributing to delays in lenalidomide acquisition from a health equity perspective. The secondary endpoint was to determine the median time from prescription generation to dispensation.ResultsWe included 328 patients with a mean age of 71 years; 53% were male and 80% were White. Comorbidities included cardiovascular disease (53%), diabetes (15%), obesity (21%), respiratory disease (8%), and chronic kidney disease (7%). Eighteen percent of patients required transportation assistance. The primary endpoint revealed 54% required financial assistance, which was associated with delayed lenalidomide dispensation (P < 0.05). The secondary endpoint showed a median time of 8 days (IQR, 5-14) to dispense the prescription.ConclusionThis study found that lenalidomide prescriptions took a median of 8 days to fill, with those requiring financial assistance experiencing longer delays. These findings suggest that insurance processes and health disparities hinder timely access.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251348222"},"PeriodicalIF":1.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suzetrigine: A potential alternative for palliative pain management in Pakistan's opioid-restricted healthcare system. Suzetrigine：在巴基斯坦阿片类药物限制的医疗保健系统中，姑息性疼痛管理的潜在替代方案。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-10 DOI: 10.1177/10781552251340330

Mahmood Memon, Sahil Kumar, Manoj Parkash, Mahek Bansari, Muaaz Mahmood, Anosh Khowaja, Sahir Bansari, Farina Fatima Siddiqui, Ayesha Almas, Muhammad Momin Khan

{"title":"Suzetrigine: A potential alternative for palliative pain management in Pakistan's opioid-restricted healthcare system.","authors":"Mahmood Memon, Sahil Kumar, Manoj Parkash, Mahek Bansari, Muaaz Mahmood, Anosh Khowaja, Sahir Bansari, Farina Fatima Siddiqui, Ayesha Almas, Muhammad Momin Khan","doi":"10.1177/10781552251340330","DOIUrl":"https://doi.org/10.1177/10781552251340330","url":null,"abstract":"BackgroundPalliative care aims to improve the quality of life for patients with terminal illnesses by addressing physical, psychological, and social needs. However, only 14% of individuals globally who need palliative care receive it. In Pakistan, the availability is critically low, with a palliative care-to-population ratio of 1:90 million. Access to strong opioids for pain relief is severely restricted, with only 2% of terminally ill patients receiving adequate analgesia. These limitations, driven by concerns over opioid misuse and regulatory restrictions, highlight the urgent need for effective, accessible non-opioid alternatives. Suzetrigine, a novel NaV1.8 channel inhibitor, may offer a promising solution.MethodsThis brief review summarizes clinical trial data from multiple Phase 2 and Phase 3 studies evaluating the efficacy and safety of Suzetrigine in managing acute and chronic pain. Primary endpoints included the time-weighted sum of pain intensity difference over 48 hours and weekly average pain score reductions assessed using the numeric pain rating scale. The implications of these findings were contextualized in the setting of Pakistan's opioid-restricted palliative care landscape.ResultsSuzetrigine demonstrated statistically and clinically significant analgesic effects in trials involving postoperative pain, lumbar radiculopathy, and diabetic neuropathy. The drug was well-tolerated, with adverse events such as nausea, headache, and constipation being mild and infrequent.ConclusionSuzetrigine presents a viable non-opioid analgesic alternative for palliative care in Pakistan, where regulatory and systemic barriers limit opioid access. Its introduction could enhance pain management, reduce opioid-related harms, and support the development of a safer, more accessible palliative care model.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251340330"},"PeriodicalIF":1.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and management of oxaliplatin hypersensitivity. 奥沙利铂超敏反应的特点及处理。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-03 DOI: 10.1177/10781552251342204

Daniel J Tobben, Jennifer Miller, Nicole Soriano

{"title":"Characteristics and management of oxaliplatin hypersensitivity.","authors":"Daniel J Tobben, Jennifer Miller, Nicole Soriano","doi":"10.1177/10781552251342204","DOIUrl":"https://doi.org/10.1177/10781552251342204","url":null,"abstract":"Hypersensitivity reactions (HSRs) to oxaliplatin are common in patients undergoing long-term chemotherapy. Desensitization is often recommended following initial reactions but is resource-intensive and may delay treatment. This study aimed to evaluate the outcomes of a slower infusion rate when re-challenging patients with previous oxaliplatin HSRs and idenify factors associated with successful re-challenge Methods: A retrospective, observational cohort study was conducted at Northwestern Memorial Hospital, including patients who experienced HSRs to oxaliplatin and were re-challenged with a 4-h infusion between March 1, 2018, and August 1, 2023. Co-primary endpoints were the percentage of patients completing the 4-h infusion without HSR, experiencing any reaction during the infusion, and receiving further doses of oxaliplatin. Logistic regression analyzed factors associated with successful and unsuccessful re-challenge. Results: Data from 62 patients were analyzed, with a median patient age of 58 years. Ninety-seven percent of patients completed the full re-challenge dose, 79% had no documented reaction, and 77% received future doses. The Brown Criteria for grading hypersensitivity reactions was used. Among Grade 1 initial reactions, 93.5% were re-challenged without a subsequent reaction, compared to 67% with Grade 2 or 3 reactions. The grade of the initial reaction was a significant predictor of re-reaction risk upon re-challenge. Conclusion: A slower infusion rate with allowed successful re-challenge of patients with prior oxaliplatin HSRs, particularly those with Grade 1 initial reactions. These findings suggest that extended infusion protocols can effectively manage oxaliplatin HSRs, potentially reducing the need for desensitization and minimizing treatment delays.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251342204"},"PeriodicalIF":1.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Misalignment between patient preferences and clinician expectations: Do press releases make clinicians impatient to the detriment of patients? 患者偏好和临床医生期望之间的偏差：新闻发布是否会使临床医生对患者失去耐心？

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-03 DOI: 10.1177/10781552251346897

Pelayo Nieto-Gómez, Celia Castaño-Amores

引用次数: 0

Subcutaneous nivolumab: Advancing operational efficiency and patient-centred care in the NHS. 皮下纳武单抗：提高NHS的操作效率和以患者为中心的护理。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-02 DOI: 10.1177/10781552251346908

Joanne Parkes

引用次数: 0